Frontlight ResearchEarly access
Taking people in SpainPhase 2
Combined radiotherapy and chemotherapy before stem cell transplant for high-risk blood cancers
Tests a combined radiation and chemotherapy preparation before transplant in adults with high-risk blood cancer.
Key facts
- Who runs it
- Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla
- Where
- Sevilla, SpainSee the site
- Trial code
- Registry title
- Preparation for bone marrow transplant through the combined use of chemo and radiotherapy (intensive or myeloablative: eliminates stem cells)
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 49 people, planned
- Started
- 10 Feb 2025
- Expected to end
- 1 Oct 2028
- Type of study
- Interventional
- Record updated
- 24 October 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 50 with high-risk myelodysplastic syndrome or acute myeloid leukemia who are going to have a donor stem cell transplant.
- Age
- 18 to 50 years
- Sex
- Women and men can join.
- Disease stage
- High-risk myelodysplastic syndrome or acute myeloid leukemia that has come back or does not respond to treatment, or is in remission with traces of disease still measurable.
- Earlier treatment
- At least 14 days must have passed since the last induction or reinduction cycle. People with a past transplant using their own cells in the last year, or a past donor transplant at any time, cannot join. Previous radiation therapy that rules out total marrow and lymphoid irradiation also excludes.
- Biomarker or test result
- A donor is needed: a sibling with identical HLA (A, B, C, DR) or an 8/8 matched unrelated donor. One allele difference in A, B, C or DRB1 is allowed. For FLT3-ITD-mutated leukemia, traces of disease can be shown by next-generation sequencing.
Main reasons for not taking part
- Earlier autologous transplant within the last year, or any earlier donor transplant
- Earlier radiation therapy that rules out total marrow and lymphoid irradiation
- Uncontrolled disease, including ongoing or active infection
- Other active cancer
- Allergic reaction to substances similar to cyclophosphamide or etoposide
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- The participant has the ability and willingness to sign the informed consent document
- Pulmonary function tests: forced expiratory volume in one second (FEV1) and Carbon Monoxide Diffusion Capacity (DLCO) (adjusted for Hb) ≥ 50% from expected normal value; Patients should undergo cardiac evaluation with an electrocardiogram showing no ischemic changes or clinically relevant arrhythmia, and a ≥50% ejection fraction established by Multi-Gated Acquisiton Scan (MUGA) or echocardiogram; ECG showing no ischemic changes or clinically significant arrhythmia; Men and women of childbearing potential agree to use appropriate contraceptives (hormonal or barrier contraception or abstinence) prior to study entry and for six months following the duration of study participation; The time elapsed since the end of the last induction or reinduction cycle must be greater than or equal to 14 days; Age ≥18 to ≤50 years; Karnofsky’s performance status should be ≥70%; Patients with myelodysplastic syndrome/acute myeloid leukemia or acute myeloid leukemia with relapsed/refractory active disease, or in complete remission or morphologic leukemia-free state with evidence of measurable residual disease as assessed by multiparameter flow cytometry (≥ 0,1%) or next-generation sequencing (in the case of FLT3-ITD-mutated AML); All candidates for this study must have an HLA (A, B, C, DR) identical siblings who are willing to donate bone marrow or peripheral blood hematopoietic progenitors or an 8/8 matched unrelated donor. A single allele mismatch in A, B, C or DRB1 shall be allowed; Total bilirubin ≤ 1.5 x ULN OR 3 x ULN for Gilbert's disease; SGOT & SGPT ≤ 5 x LSN; Serum creatinine ≤ 1.3 mg/dL or creatinine clearance measured ≥ 80 mL/min for 24 hours of urine collection; Women of childbearing age only: Negative urine or serum pregnancy test
Who cannot take part
- Patients who have received a previous autologous (within the last year) or allogeneic transplant (at any time) are excluded
- Previous radiation therapy, which would preclude the use of TMLI
- Uncontrolled disease, including ongoing or active infection
- History of allergic reactions attributed to compounds of chemical or biological composition similar to cyclophosphamide or etoposide
- Patients with other active malignancies are not eligible for this study, other than the malignancies discussed
- Patients with a psychological or medical condition that the patient's physician deems unacceptable to proceed with allogeneic hematopoietic stem cell transplantation
- Subjects who, in the opinion of the investigator, may not be able to meet the safety control requirements of the study
- Plans during the trial to receive any other investigational (non-trial-related) agents
- Women who plan to become pregnant or breastfeed during the trial
- Patients who do not agree to practice effective forms of contraception
Where in Spain
- University Hospital Virgen Del Rocio S.L.Sevilla, SpainTaking people
About the trial
What the trial wants to find out
The antitumor activity of the conditioning regimen with TMLI, cyclophosphamide and etoposide followed by AHSCT will be evaluated by means of the progression-free survival (PFS) at 2 years after a safety-lead phase.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- PHASE II STUDY OF TOTAL MARROW AND LYMPHOID IRRADIATION (TMLI) ADMINISTERED IN COMBINATION WITH A MYELOABLATIVE REGIMEN BASED ON CYCLOPHOSPHAMIDE AND ETOPOSIDE AS A CONDITIONING FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT) IN PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA
- Plain-language title
- Combined radiotherapy and chemotherapy before stem cell transplant for high-risk blood cancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 11 November 2026.
- Record updated
- 24 October 2025